Azenta FY 2026: Revenue $621.7M, EPS ($3.7) — 10-K Summary
Azenta reported FY 2026 revenue of $621.7M, up 4.7% YoY, but net loss widened to $166.99M due to a $149.1M goodwill impairment charge. Both segments saw revenue growth, while gross margin declined to 44.2%. The company expects $11M in annual cost savings from a restructuring plan.
How this was made

The 30-second read
Why it matters
The headline trading relevance is the combination of revenue growth with a much wider net loss, driven by a large non-cash goodwill impairment, plus margin compression and inventory reserve pressure. The stated annualized cost savings from restructuring provides a forward-looking offset but is not quantified beyond the $11.0M target.
Market read
For traders, the impairment and margin/inventory drivers are the immediate sentiment catalysts, while the restructuring savings target is the main medium-term offset to monitor.
What to watch
Gross margin decline is attributed to fixed-cost absorption, rework costs, and excess/obsolete inventory reserves, so traders should watch whether inventory normalization and restructuring execution reverse the margin trend.
Background
The piece summarizes Azenta’s FY 2026 results from its Nov. 19, 2026 10-K, including segment revenue changes and a Multiomics restructuring plan.
Ticker impact
Azenta reports FY 2026 revenue of $621.7M (+4.7% YoY) and a widened net loss driven by a $149.1M non-cash goodwill impairment charge.
Likely downside bias as investors focus on the large goodwill impairment and margin compression, with some stabilization if cost-savings execution is credible.
The article’s key incremental datapoints are the impairment charge, net loss/EPS deterioration, gross margin decline, and the stated annualized cost-savings target from the Multiomics restructuring plan.
Market effects
Signals ongoing profitability pressure and balance-sheet write-down risk in life-science tools and services, with restructuring as the primary lever.
Limited direct regional spillover; mainly affects US-listed life-science services sentiment.
Modest, as the disclosed drivers are company-specific (impairment, inventory reserves, restructuring) rather than a global demand shock.
Counterpoint
The impairment is non-cash, so the market may overreact if operating cash generation and restructuring savings offset the accounting hit.
Key entities
- companyAzenta, Inc.
US-listed life-science tools and services provider reporting FY 2026 revenue growth, a large goodwill impairment, and a Multiomics restructuring cost-savings plan.


